anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this project, the investigators aim to test the effectiveness of a mobile health (mHealth) system as a standalone versus coach-assisted intervention with the goal of achieving reach and scalability. Aim 1 is to evaluate the effectiveness of the UseIt! mHealth system as both a standalone and coach-assisted intervention compared to a control app condition. Aim 2 is to assess target (parent management training/cognitive behavioral therapy skill acquisition and use) engagement and validation. Aim 3 is to evaluate the effectiveness of the components of the UseIt! mHealth system. The investigators plan to recruit an anticipated total of 324 families for the study. Families will be randomly assigned to Group 1 (standalone app), Group 2 (coach-assisted), or Group 3 (control app condition). Parents will use the app for four months before the administration of the post-treatment assessment. Parents will be trained to use the UseIt! mHealth system over the phone. The coach for the Group 2 condition will be a bachelor's level paraprofessional with a degree in psychology or an allied discipline (e.g., social work) who will provide support to parents. The system is very user friendly and families can be trained in approximately 30 minutes. Assessments will take place at Baseline, Post (4 months from baseline), and 6-month follow-up. All assessments will be conducted online (Qualtrics survey links sent via email by research staff) and take approximately 1 hour to complete.
PROBLEM TO BE SOLVED: To deal with the limitations of the present heart transplantation methodologies existing in the therapy for heart diseases.SOLUTION: Muscle cells and methods for using the muscle cells are provided. In one embodiment, transplantable skeletal muscle cell compositions and the methods of use thereof are provided. In one embodiment, the muscle cells can be transplanted into subjects having disorders characterized by insufficient cardiac function, e.g. congestive heart failure, by administering the skeletal myoblasts to the subjects. The muscle cells can be autologous, allogeneic, or xenogeneic to the recipient. Furthermore, modification, masking or removal of antigens existing on the surface of the cells in the compositions to inhibit the lysis of the cells, when administering the compositions to the subjects are proposed.
This study will examine participant's fitness levels before and after a 16 week intervention period. There are two study visits prior to starting the intervention period. During Baseline Study Visit #1, the investigators will take a health history, determine the height and weight of the participants, and have participants complete a physical activity questionnaire and a 3-day diet log, as well as determine muscle and fat mass, followed by tests that examine how blood vessels function, and lastly a treadmill test to determine aerobic fitness. During Baseline Study Visit #2, which takes place 5-7 days later, the investigators will measure blood pressure, heart rate, and glucose control through a glucose challenge test. The glucose challenge tests requires taking \~3 Tablespoons of blood to be assessed for glucose, insulin and hemoglobin A1c. Lastly, participants will complete 3 questionnaires regarding quality of life, fatigue, and depression.

After completion of the two pre-training data collection visits, participants will be randomized to 1 of 3 groups: 1) HRV-guided exercise group (HRV); 2) traditional exercise training group (TRAD); or 3) usual care group. There will be approximately 30 subjects in each group, providing an equal chance of being assigned to either group. Both the HRV and TRAD groups will participate in a combined lab-supervised and home-based exercise program (with 1 day1 per week supervised in the laboratory and 3 days per week at home) over the course of 16 weeks. Furthermore, both exercise groups will participate in online/phone counseling in order to provide support. Specifically, participants will be provided with a phone number to the lab to call study personnel for assistance if needed. Weekly internet video chats through Zoom or phone calls, if Zoom is unavailable, will be conducted by a trained exercise-behavior change coach to help participants focus on self-efficacy, outcome expectations, impediments (barriers), and goal setting.

Post-training testing Visits #3 and #4 Visits #3 and #4 will be identical to visits #1 and 2, with the exception that the demographic questionnaire will not be administered again. This will mean there is a total of 100 mL of blood taken over the course of the entire study, between Visits 2 and 4 combined, which will total \~6 total Tablespoons.
Patients will be given a single oral or IV loading dose of TXA within three hours of being randomized or whenever possible prior to surgery. Patients who are able to swallow will be given an oral loading dose of 1g TXA. Patients who are unable to swallow will be given an IV loading dose of 1g TXA which will be added to a 100mL infusion bag of NaCl 0.9% and infused by slow intravenous injection over 20 minutes as per the recommended rate of administration in the Product Monograph for Sandoz-Tranexamic Acid Injection BP. After 12 hours of the loading dose, patients will be given 500mg TXA by mouth (or 500mg TXA in NaCl 0.9% 100mL by IV for those unable to swallow) three times daily, totalling 1500mg/day, for 45 days.
PURPOSE:To obtain a cosmetic, having skin beautifying and adjusting action based on wound curing promoting effects as well as excellent feeling of used and stability, by blending rosmarinic acid and/or salt thereof. CONSTITUTION:A cosmetic, obtained by blending rosmarinic acid, expressed by the formula and obtained by extracting a plant of the family Labiatae, preferably Rosmarinus officinalis L. (rosemary), Perilla frutescens Britton var. acuta Kudo, Perilla frutescens Britton var. crispa Decaisne f. viridi-crispa Makino, Agastache rugosa O. Kuntze, Isodon japonicus Hara, etc., particularly Rosmarinus officinalis L. or Perilla frutescens Britton var. crispa Decaisne f. viridi-crispa Makino and/or a salt thereof as an active ingredient in an amount of 0.005-5wt%, particularly 0.1-3wt% based on the total weight of the cosmetic and preferably further adding a water-soluble high polymer substance, e.g. polypeptide, soluble collagen, mucopolysaccharides, etc. and having the above-mentioned effects. Furthermore, the afore-mentioned active ingredient has also hair tonic effects in addition to the above-mentioned effects when using as a hair cosmetic.
Although the prevalence of MINOCA is about 5-25% of all myocardial infarctions and the prognosis is now recognised as inauspicious, with a one-year all-cause mortality rate of 3.5%, data on the specific demographics, clinical features, etiopathogenetic factors and prognosis of MINOCA patients are still currently unavailable in Italy. The aim of this study is to assess, in a real-world setting, prevalence, demographics, possible aetiological causes and diagnostic, therapeutic and prognostic data of MINOCA patients in Italy by creating a national database with ambispectively collected data. The collection of therapeutic and management data on MINOCA in an ambispective manner - retrospective and prospective patients - will make it possible to evaluate the hospital management of MINOCA and its association with patient prognosis over time. This database will serve to determine the incidence and characteristics of this pathology. In addition, it will make it possible to evaluate the nationwide management of patients with MINOCA, thus considering both the diagnostic aspects aimed at defining the aetiology, and cascade the treatments used and the patients' outcomes. As in all observational studies, the assessment of the risk/benefit ratio of patients with myocardial infarction, the administration of medical treatment and the management of the disease and treatment-related clinical events are the responsibility of the physician treating the patient. Since the purpose of the work only involves the collection of data, participation in this research will not entail any additional risk for the patient. The collection of actual data should provide valuable information on the demographics, aetiology and prognosis of MINOCA patients.
Prednisone tablets contain prednisone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone is a white to practically white, odorless, crystalline powder. It is very slightly soluble in water; slightly soluble in alcohol, in chloroform, in dioxane, and in methanol.

The chemical name for prednisone is pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- and its molecular weight is 358.43.

The structural formula is represented below:

Prednisone Tablets, USP are available in 2 strengths: 2.5 mg and 5 mg. Inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch (corn), sodium starch glycolate (potato), and stearic acid.
PURPOSE:To obtain the titled composition preventing reduction in enzyme activity, useful as an intracorporeal adhesion inhibitor, by supporting an enzyme or a medicinal component capable of bonding to a neutral amino acid by amino bond on a polyamino acid through the neutral amino acid or an oligopeptide thereof. CONSTITUTION:An enzyme (e.g. lipoprotein or lipase) or a medicinal component (e.g. germicide or carcinostatic agent) capable of bonding to a neutral amino acid glycine, alanine or leucine is supported on a polyamino acid (e.g. polymer of glutamic acid or leucine or copolymer thereof) through the neutral amino acid or an oligopeptide thereof as a spacer. Since durability of repeated use of enzyme and thermostability are improved by the method and pH dependence is lowered, the titled composition has high specific activity and durable effects.
No intervention was performed on patients in this group. Followed for 6 weeks. Face-to-face meetings were held once a week.
PCT No. PCT/UA94/00026 Sec. 371 Date Aug. 9, 1995 Sec. 102(e) Date Aug. 9, 1995 PCT Filed Oct. 17, 1994 PCT Pub. No. WO95/16455 PCT Pub. Date Jun. 22, 1995The invention relates, generally, to medicine, and particularly to cell therapy. Claimed is a medicinal preparation characterized by a certain composition and quantitative parameters of a cell suspension prepared from native or cryopreserved hemopoietic liver and/or spleen cells of a human embryo. Furthermore, claimed is a method of treating acquired immune deficiency syndrome (HIV infection) by administering the above medicinal preparation that is chosen from a tissue bank of various samples, taking into account individual indices of a patient, the same sample of preparation being used in repeated administration.
Accumulating evidence indicates that the lysosomal Ragulator complex is essential for full activation of the mechanistic target of rapamycin complex 1 (mTORC1). Abnormal mTORC1 activation has been implicated in several developmental neurological disorders, including Angelman syndrome (AS), which is caused by maternal deficiency of the ubiquitin E3 ligase UBE3A. Here, it is reported that Ube3a regulates mTORC1 signaling by targeting p18, a subunit of the Ragulator. Ube3a ubiquinates p18, resulting in its proteasomal degradation, and Ube3a deficiency in the hippocampus of AS mice induces increased lysosomal localization of p18 and other members of the Ragulator-Rag complex, and increased mTORC1 activity. p18 knockdown in hippocampal CA1 neurons of AS mice reduces elevated mTORC1 activity and improves dendritic spine maturation, long-term potentiation (LTP), as well as learning performance. The results described herein indicate that Ube3a-mediated regulation of p18 and subsequent mTORC1 signaling is critical for typical synaptic plasticity, dendritic spine development, and learning and memory.
Pathogenic variants in LMNA have been associated with a wide spectrum of muscular conditions: the laminopathies. LMNA-related congenital muscular dystrophy is a laminopathy characterised by the early onset of symptoms and often leads to a fatal outcome at young ages. Children face a heightened risk of malignant arrhythmias. No established paediatric protocols for managing this condition are available. We review published cases and provide insights into disease progression in two twin sisters with LMNA-related muscular dystrophy. Our objective is to propose a cardiac surveillance and management plan tailored specifically for paediatric patients. We present a family of five members, including two twin sisters with LMNA-related muscular dystrophy. A comprehensive neuromuscular and cardiac work-up was performed in all family members. Genetic analysis using massive sequencing technology was performed in both twins. Clinical assessment showed that only the twins showed diagnoses of LMNA-related muscular dystrophy. Follow-up showed an early onset of symptoms and life-threatening arrhythmias, with differing disease progressions despite both twins passing away. Genetic analysis identified a de novo rare missense deleterious variant in the LMNA gene. Other additional rare variants were identified in genes associated with myasthenic syndrome. Early-onset neuromuscular symptoms could be related to a prognosis of worse life-threatening arrhythmias in LMNA related muscular dystrophy. Being a carrier of other rare variants may be a modifying factor in the progression of the phenotype, although further studies are needed. There is a pressing need for specific cardiac recommendations tailored to the paediatric population to mitigate the risk of malignant arrhythmias.
Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with growth deceleration were assigned to the GH treatment group in accordance with standard of care. Subjects with normal growth were randomized to treatment or to control (no intervention). The intervention was Nutropin AQ. The starting dose was calculated as 0.3 mg/kg/wk and subsequently modified based on observed length/height velocity and serum IGF-I levels.
Toothpaste compositions, for treatment of hypersensitive dentin, comprise non-toxic ionizable strontium salts in an aqueous solution, which also contains a surface-active wetting agent compatible with strontium ions, the said compositions being free from appreciable amounts of substances which precipitate strontium salts are the chloride, acetate, bromide, lactate, iodide, nitrate, or salicylate. Suitable wetting agents are polyoxyethylene partial esters of polyhydric fatty acid derivatives, polyoxyethylene-polyoxypropylene condensate, polyoxyethylene-fatty alcohol ether, or a fatty acid N-methyl taurine condensate.  The toothpaste preferably contains strontium-ion-compatible polishing agents, e.g. strontium phosphate, strontium carbonate, micronized silica, or aluminium hydroxide; and a strontium-ion-compatible bodying agent, e.g. methyl cellulose, hydroxyethyl cellulose, or high molecular weight polyoxy ethylene polymers.  Sufficient water should be present to dissolve a therapeutically active amount of the strontium compound.
An object is to prevent of display of display of candidates unlikely to be selected. An information processing device a target date associated with an input value to be input. The information processing device displays candidates for an input value on a screen. At this time, the information processing device displays a first number of candidates when the target date is included in a first period during which the information changes in a first range. The information processing device displays a second number of candidates that is smaller than the first number when the target date is included in a second period during which the information changes in a second range that is narrower than the first range. The first period and the second period is included in a cycle in which the information changes.
The investigators will study the kinetics of multiple types of high-density lipoprotein (HDL) in humans under two strictly controlled dietary conditions, high unsaturated fat and high carbohydrate, in 20 individuals with low HDL cholesterol and overweight or obesity. The participants will be given the controlled diets for 4 weeks in a randomized crossover design. They will be admitted to the Brigham \& Women's Hospital Center for Clinical Investigation (CCI) the morning of Day 28 when they will be infused intravenously with a stable isotope tracer, trideuterated (D3), leucine for 10 minutes as a bolus. Blood will be sampled in the hospital through 24 hours, and thereafter at the ambulatory clinical center throughout 94 hours. HDL subtypes will be prepared in Dr. Sacks's laboratory at Harvard School of Public Health (HSPH) and analyzed for content of lipids and proteins, and for incorporation of the tracer into apolipoprotein A-I, the principal protein of HDL. These data will be studied by interactive modeling to a multi-compartment model of human HDL physiology that best fits the observed data. The model will yield HDL metabolic rates during unsaturated fat and carbohydrate-rich diets which will be tested for statistical significance.
(A) Antigen (I) derived from malignant cells and having (1) molecular mass of 340000-400000, (2) the ability to bind to lectin wheat germ agglutinin, (3) resistance to being boiled and (4) resistance to destruction and to extn. from malignant cells with EtOH, MeOH, xylol or CHCl3-MeOH is new. Pref. (I) is destructable on digestion with pronase; it has a molecular mass component of 350000-490000, a glycoprotein structure with a high carbohydrate content and an isoelectric point of 6.8-7. (B) Monoclonal antibody directed at human tumour cells and recognising and binding with (I) is new. (C) Prodn. of immunogens comprises prepn. of an extract from a cultured cell line derived from human cancer cells, contact of the extract with lectin wheat germ agglutinin for binding of the immunogens to it, elution of non-bonded material and stripping of the immunogens from the agglutinin. (D) Cell culture medium for use in the prepn. of a monoclonal antibody and deposited as CNCM No. 1-195 is new. The (I) is present in the cell membrane of malignant cancer cells and it is obtd. from them by extn. etc. (I) is determined in a tissue specimen by use of an antibody, esp. a monoclonal antibody, in locating malignant tumours in clinical diagnosis.
INTRODUCTION: This study introduces and compares a new intraperitoneal laparoscopic para-aortic lymphadenectomy method to reach the level of the renal vein, the "tent-pitching" antegrade approach with the retrograde approach in gynecological malignancy surgeries in terms of success rate, complication incidence, and the number of lymph nodes removed. It focuses on the feasibility, safety, and effectiveness. Meanwhile, this article reports on the vascular anatomical variations discovered in the para-aortic region to enhance surgical safety.
MATERIAL AND METHODS: This was a retrospective cohort study including patients undergone laparoscopic para-aortic lymphadenectomy at a single center from January 2020 to December 2023 for high-risk endometrial and early-stage ovarian cancer. Patient charts were reviewed for mode of operation, perioperative complications, operative details, and histopathology. The patients were divided into anterograde group and retrograde group according to the operation mode. The two groups were further compared based on the success rate of lymph node clearance at the renal vein level, perioperative complications, and the number of removed lymph nodes. Quantitative data were analyzed using the t-test, non-normally distributed data using the rank-sum test, and categorical data using Fisher's exact test and the chi-square test, with statistical significance defined as P < 0.05.
RESULTS: Among 173 patients, the antegrade group showed higher surgery success (97.5% vs 68.82%), more lymph nodes removed (median 14 vs 7), and less median blood loss. The operation time was shorter in the antegrade group. Postoperative complications like lymphocele and venous thrombosis were lower in the antegrade group. Vascular abnormalities were found in 28.9% of patients, with accessory lumbar vein routing anomaly and accessory renal arteries being most common.
CONCLUSIONS: The antegrade approach is feasible, safe, and effective, improving surgical exposure, reducing difficulty without additional instruments or puncture sites, and minimizing organ damage risk. It is effective in achieving better access to the renal vein and removing more para-aortic lymph nodes than the retrograde method. Recognizing and carefully managing the diverse vascular abnormalities in the para-aortic area, including variations in renal arteries, veins, and the inferior vena cava, is essential to reduce intraoperative bleeding and the likelihood of converting to open surgery.
PURPOSE: To analyze our experience with vNOTES gynecologic procedures in women with morbid and super morbid obesity to determine feasibility and compare outcomes with standard minimally invasive techniques.
METHODS: Gynecologic procedures performed by three surgeons on women with a body mass index (BMI) ≥ 40 kg/m2 from 2017 to 2023. A subset of women with a BMI ≥ 50 kg/m2 was also analyzed.
RESULTS: 103 women with a BMI ≥ 40 kg/m2 were identified (Class IV), 19 of whom had a BMI ≥ 50 kg/m2 (Class V). For the entire population the mean BMI was 45.7 kg/m2 (40-62). 29 women were nulliparous and 23 had at least one prior cesarean delivery. 51 had no prior abdominal surgery. The procedures performed were hysterectomy and removal of adnexae in 77 patients, hysterectomy alone in six, adnexal surgery alone in nine, and hysterectomy with adnexectomy and lymph nodes in five. Two surgeries were converted to laparoscopy and five to laparotomy. Average surgical time was 87 min (30-232). Average blood loss was 82 mL (10-400). Mean uterine weight was 206 g (29-2890). 53 procedures were performed as outpatient, 44 had overnight observation, four had a length of stay of 2 days, one each for 4 days and 5 days. The laparoscopies occurred in one patient with an obliterated cul-de-sac and in one patient for lymph node removal. The laparotomies occurred for adnexal adhesions in one, bleeding in two, a cystotomy in one requiring urology consultation, and an obliterated cul-de-sac One patient developed a postoperative vaginal cuff hematoma not requiring intervention.
CONCLUSION: vNOTES gynecologic procedures are feasible in this high-risk population and may result in shorter recovery times and fewer complications than standard laparoscopy or transvaginal surgery. What does this study add to the clinical work: VNOTES approach is feasible in morbidly obese women and may have distinct advantages over conventional laparoscopic, vaginal or open techniques.
MAPK-activating death domain protein (MADD) deficiency is associated with a broad clinical spectrum ranging from mild developmental impairment to fatal multisystem disorder. We report an additional case of severe form with some overlapping and unreported systemic features in a growth-restricted full-term male newborn. The novel findings include corpus callosum agenesis, bilateral adrenal agenesis, scrotal aplasia, and abnormal skin pigmentation. Microscopic changes are only remarkable in thyroid gland that shows decreased, variously sized follicles with absent or non-vacuolated pale colloid. This unique constellation of birth defects is associated with a novel homozygous in-frame MADD gene deletion (NM_003682.4: c.4853_4855delGCT:p.Cys1618del). This case report expands the phenotypic and genetic spectrum of MADD deficiency.
Single agent CPX-351 administered at the standard FDA approved dose of 44 mg/m2 intravenously on days 1, 3, 5 of the induction cycle. If participants achieve complete remission (CR), complete remission with incomplete count recovery (CRi) or partial remission (PR), they will be eligible to continue on to maintenance therapy, which will consist of CPX351 at a dose of 15.4 mg/m2 every 28 days. Participants can receive up to 4 cycles of maintenance therapy.